Ovarian Disease - Pipeline Review, H2 2012

Global Markets Direct, August 2012, Pages: 39

Ovarian Disease – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Ovarian Disease - Pipeline Review, H2 2012', provides an overview of the Ovarian Disease therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Disease. 'Ovarian Disease - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ovarian Disease.
- A review of the Ovarian Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ovarian Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ovarian Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ovarian Disease pipeline depth and focus of Ovarian Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Ovarian Disease Therapeutic Products under Development, Key Players in Ovarian Disease Therapeutics, Ovarian Disease Pipeline Overview, Ovarian Disease Pipeline, Ovarian Disease Pipeline Assessment

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Ovarian Disease Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Ovarian Disease 7
Ovarian Disease Therapeutics under Development by Companies 9
Ovarian Disease Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Ovarian Disease Therapeutics – Products under Development by Companies 16
Ovarian Disease Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Ovarian Disease Therapeutics Development 18
Respiratorius AB 18
Ovarian Disease – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
SPOC - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Cyclophosphamide + Goserelin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Estradiol Patch - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Methylprednisolone - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Leuprolide Acetate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Merional - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Triptorelin + Norethisterone Acetate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cabergoline - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DHEA - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Ovarian Disease Therapeutics – Drug Profile Updates 36
Ovarian Disease Therapeutics - Dormant Products 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Number of Products Under Development for Ovarian Disease, H2 2012 7
Products under Development for Ovarian Disease – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Respiratorius AB, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Ovarian Disease Therapeutics – Drug Profile Updates 36
Ovarian Disease Therapeutics – Dormant Products 37

List of Figures
Number of Products under Development for Ovarian Disease, H2 2012 7
Products under Development for Ovarian Disease – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Customers who bought this item also bought

• Oncology Intelligence: A Comprehensive Report for Decision Making
• Drug Addiction – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013